Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Innovations in addressing pediatric diarrhea in low resource settings.

Jumani RS, Spector JM, Izadnegahdar R, Kelly P, Diagana TT, Manjunatha UH.

ACS Infect Dis. 2019 Oct 15. doi: 10.1021/acsinfecdis.9b00315. [Epub ahead of print]

PMID:
31612701
2.

Development of a Cytopathic Effect-Based Phenotypic Screening Assay against Cryptosporidium.

Chao AT, Lee BH, Wan KF, Selva J, Zou B, Gedeck P, Beer DJ, Diagana TT, Bonamy GMC, Manjunatha UH.

ACS Infect Dis. 2018 Apr 13;4(4):635-645. doi: 10.1021/acsinfecdis.7b00247. Epub 2018 Jan 25.

PMID:
29341586
3.

A Cryptosporidium PI(4)K inhibitor is a drug candidate for cryptosporidiosis.

Manjunatha UH, Vinayak S, Zambriski JA, Chao AT, Sy T, Noble CG, Bonamy GMC, Kondreddi RR, Zou B, Gedeck P, Brooks CF, Herbert GT, Sateriale A, Tandel J, Noh S, Lakshminarayana SB, Lim SH, Goodman LB, Bodenreider C, Feng G, Zhang L, Blasco F, Wagner J, Leong FJ, Striepen B, Diagana TT.

Nature. 2017 Jun 15;546(7658):376-380. doi: 10.1038/nature22337. Epub 2017 May 31.

4.

Cryptosporidiosis Drug Discovery: Opportunities and Challenges.

Manjunatha UH, Chao AT, Leong FJ, Diagana TT.

ACS Infect Dis. 2016 Aug 12;2(8):530-7. doi: 10.1021/acsinfecdis.6b00094. Epub 2016 Jul 22. Review.

PMID:
27626293
5.

Pyrrolo[3,4-c]pyridine-1,3(2H)-diones: A Novel Antimycobacterial Class Targeting Mycobacterial Respiration.

van der Westhuyzen R, Winks S, Wilson CR, Boyle GA, Gessner RK, Soares de Melo C, Taylor D, de Kock C, Njoroge M, Brunschwig C, Lawrence N, Rao SP, Sirgel F, van Helden P, Seldon R, Moosa A, Warner DF, Arista L, Manjunatha UH, Smith PW, Street LJ, Chibale K.

J Med Chem. 2015 Dec 10;58(23):9371-81. doi: 10.1021/acs.jmedchem.5b01542. Epub 2015 Nov 20.

PMID:
26551248
6.

Structure activity relationships of 4-hydroxy-2-pyridones: A novel class of antituberculosis agents.

Ng PS, Manjunatha UH, Rao SP, Camacho LR, Ma NL, Herve M, Noble CG, Goh A, Peukert S, Diagana TT, Smith PW, Kondreddi RR.

Eur J Med Chem. 2015 Dec 1;106:144-56. doi: 10.1016/j.ejmech.2015.10.008. Epub 2015 Oct 14.

PMID:
26544629
7.

Comprehensive physicochemical, pharmacokinetic and activity profiling of anti-TB agents.

Lakshminarayana SB, Huat TB, Ho PC, Manjunatha UH, Dartois V, Dick T, Rao SP.

J Antimicrob Chemother. 2015 Mar;70(3):857-67. doi: 10.1093/jac/dku457. Epub 2014 Nov 11.

PMID:
25587994
8.

Perspective: Challenges and opportunities in TB drug discovery from phenotypic screening.

Manjunatha UH, Smith PW.

Bioorg Med Chem. 2015 Aug 15;23(16):5087-97. doi: 10.1016/j.bmc.2014.12.031. Epub 2014 Dec 24. Review.

9.

Direct inhibitors of InhA are active against Mycobacterium tuberculosis.

Manjunatha UH, S Rao SP, Kondreddi RR, Noble CG, Camacho LR, Tan BH, Ng SH, Ng PS, Ma NL, Lakshminarayana SB, Herve M, Barnes SW, Yu W, Kuhen K, Blasco F, Beer D, Walker JR, Tonge PJ, Glynne R, Smith PW, Diagana TT.

Sci Transl Med. 2015 Jan 7;7(269):269ra3. doi: 10.1126/scitranslmed.3010597.

10.

Pharmacokinetics-pharmacodynamics analysis of bicyclic 4-nitroimidazole analogs in a murine model of tuberculosis.

Lakshminarayana SB, Boshoff HI, Cherian J, Ravindran S, Goh A, Jiricek J, Nanjundappa M, Nayyar A, Gurumurthy M, Singh R, Dick T, Blasco F, Barry CE 3rd, Ho PC, Manjunatha UH.

PLoS One. 2014 Aug 20;9(8):e105222. doi: 10.1371/journal.pone.0105222. eCollection 2014.

11.

Indolcarboxamide is a preclinical candidate for treating multidrug-resistant tuberculosis.

Rao SP, Lakshminarayana SB, Kondreddi RR, Herve M, Camacho LR, Bifani P, Kalapala SK, Jiricek J, Ma NL, Tan BH, Ng SH, Nanjundappa M, Ravindran S, Seah PG, Thayalan P, Lim SH, Lee BH, Goh A, Barnes WS, Chen Z, Gagaring K, Chatterjee AK, Pethe K, Kuhen K, Walker J, Feng G, Babu S, Zhang L, Blasco F, Beer D, Weaver M, Dartois V, Glynne R, Dick T, Smith PW, Diagana TT, Manjunatha UH.

Sci Transl Med. 2013 Dec 4;5(214):214ra168. doi: 10.1126/scitranslmed.3007355.

12.

Design, synthesis, and biological evaluation of indole-2-carboxamides: a promising class of antituberculosis agents.

Kondreddi RR, Jiricek J, Rao SP, Lakshminarayana SB, Camacho LR, Rao R, Herve M, Bifani P, Ma NL, Kuhen K, Goh A, Chatterjee AK, Dick T, Diagana TT, Manjunatha UH, Smith PW.

J Med Chem. 2013 Nov 14;56(21):8849-59. doi: 10.1021/jm4012774. Epub 2013 Oct 22.

PMID:
24090347
13.

Structure of Ddn, the Deazaflavin-Dependent Nitroreductase from Mycobacterium tuberculosis Involved in Bioreductive Activation of PA-824.

Cellitti SE, Shaffer J, Jones DH, Mukherjee T, Gurumurthy M, Bursulaya B, Boshoff HI, Choi I, Nayyar A, Lee YS, Cherian J, Niyomrattanakit P, Dick T, Manjunatha UH, Barry CE 3rd, Spraggon G, Geierstanger BH.

Structure. 2013 Jan 8;21(1):191. doi: 10.1016/j.str.2012.12.012. Epub 2013 Jan 8. No abstract available.

14.

A novel F(420) -dependent anti-oxidant mechanism protects Mycobacterium tuberculosis against oxidative stress and bactericidal agents.

Gurumurthy M, Rao M, Mukherjee T, Rao SP, Boshoff HI, Dick T, Barry CE 3rd, Manjunatha UH.

Mol Microbiol. 2013 Feb;87(4):744-55. doi: 10.1111/mmi.12127. Epub 2012 Dec 28.

15.

Structure of Ddn, the deazaflavin-dependent nitroreductase from Mycobacterium tuberculosis involved in bioreductive activation of PA-824.

Cellitti SE, Shaffer J, Jones DH, Mukherjee T, Gurumurthy M, Bursulaya B, Boshoff HI, Choi I, Nayyar A, Lee YS, Cherian J, Niyomrattanakit P, Dick T, Manjunatha UH, Barry CE 3rd, Spraggon G, Geierstanger BH.

Structure. 2012 Jan 11;20(1):101-12. doi: 10.1016/j.str.2011.11.001.

16.

Substrate specificity of the deazaflavin-dependent nitroreductase from Mycobacterium tuberculosis responsible for the bioreductive activation of bicyclic nitroimidazoles.

Gurumurthy M, Mukherjee T, Dowd CS, Singh R, Niyomrattanakit P, Tay JA, Nayyar A, Lee YS, Cherian J, Boshoff HI, Dick T, Barry CE 3rd, Manjunatha UH.

FEBS J. 2012 Jan;279(1):113-25. doi: 10.1111/j.1742-4658.2011.08404.x. Epub 2011 Nov 14.

17.

Structure-activity relationships of antitubercular nitroimidazoles. 3. Exploration of the linker and lipophilic tail of ((s)-2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazin-6-yl)-(4-trifluoromethoxybenzyl)amine (6-amino PA-824).

Cherian J, Choi I, Nayyar A, Manjunatha UH, Mukherjee T, Lee YS, Boshoff HI, Singh R, Ha YH, Goodwin M, Lakshminarayana SB, Niyomrattanakit P, Jiricek J, Ravindran S, Dick T, Keller TH, Dartois V, Barry CE 3rd.

J Med Chem. 2011 Aug 25;54(16):5639-59. doi: 10.1021/jm1010644. Epub 2011 Jul 26.

18.

Fishing the target of antitubercular compounds: in silico target deconvolution model development and validation.

Prathipati P, Ma NL, Manjunatha UH, Bender A.

J Proteome Res. 2009 Jun;8(6):2788-98. doi: 10.1021/pr8010843.

PMID:
19301903
19.

Structure-activity relationships of antitubercular nitroimidazoles. 2. Determinants of aerobic activity and quantitative structure-activity relationships.

Kim P, Kang S, Boshoff HI, Jiricek J, Collins M, Singh R, Manjunatha UH, Niyomrattanakit P, Zhang L, Goodwin M, Dick T, Keller TH, Dowd CS, Barry CE 3rd.

J Med Chem. 2009 Mar 12;52(5):1329-44. doi: 10.1021/jm801374t.

20.

Structure-activity relationships of antitubercular nitroimidazoles. 1. Structural features associated with aerobic and anaerobic activities of 4- and 5-nitroimidazoles.

Kim P, Zhang L, Manjunatha UH, Singh R, Patel S, Jiricek J, Keller TH, Boshoff HI, Barry CE 3rd, Dowd CS.

J Med Chem. 2009 Mar 12;52(5):1317-28. doi: 10.1021/jm801246z.

21.

Synthesis and antitubercular activity of 7-(R)- and 7-(S)-methyl-2-nitro-6-(S)-(4-(trifluoromethoxy)benzyloxy)-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazines, analogues of PA-824.

Li X, Manjunatha UH, Goodwin MB, Knox JE, Lipinski CA, Keller TH, Barry CE 3rd, Dowd CS.

Bioorg Med Chem Lett. 2008 Apr 1;18(7):2256-62. doi: 10.1016/j.bmcl.2008.03.011. Epub 2008 Mar 7.

22.

Mycobacterium leprae is naturally resistant to PA-824.

Manjunatha UH, Lahiri R, Randhawa B, Dowd CS, Krahenbuhl JL, Barry CE 3rd.

Antimicrob Agents Chemother. 2006 Oct;50(10):3350-4.

23.

The impact of genomics on discovering drugs against infectious diseases.

Boshoff HI, Manjunatha UH.

Microbes Infect. 2006 May;8(6):1654-61. Epub 2006 Jan 26. Review.

PMID:
16690340
24.

A complex of DNA gyrase and RNA polymerase fosters transcription in Mycobacterium smegmatis.

Gupta R, China A, Manjunatha UH, Ponnanna NM, Nagaraja V.

Biochem Biophys Res Commun. 2006 May 19;343(4):1141-5. Epub 2006 Mar 31.

PMID:
16579974
25.

Structure-activity relationships at the 5-position of thiolactomycin: an intact (5R)-isoprene unit is required for activity against the condensing enzymes from Mycobacterium tuberculosis and Escherichia coli.

Kim P, Zhang YM, Shenoy G, Nguyen QA, Boshoff HI, Manjunatha UH, Goodwin MB, Lonsdale J, Price AC, Miller DJ, Duncan K, White SW, Rock CO, Barry CE 3rd, Dowd CS.

J Med Chem. 2006 Jan 12;49(1):159-71.

26.

Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis.

Manjunatha UH, Boshoff H, Dowd CS, Zhang L, Albert TJ, Norton JE, Daniels L, Dick T, Pang SS, Barry CE 3rd.

Proc Natl Acad Sci U S A. 2006 Jan 10;103(2):431-6. Epub 2005 Dec 30.

27.

A monoclonal antibody that inhibits mycobacterial DNA gyrase by a novel mechanism.

Manjunatha UH, Maxwell A, Nagaraja V.

Nucleic Acids Res. 2005 Jun 1;33(10):3085-94. Print 2005.

28.

KpnI restriction endonuclease and methyltransferase exhibit contrasting mode of sequence recognition.

Chandrashekaran S, Manjunatha UH, Nagaraja V.

Nucleic Acids Res. 2004 Jun 10;32(10):3148-55. Print 2004.

29.

Functional characterisation of mycobacterial DNA gyrase: an efficient decatenase.

Manjunatha UH, Dalal M, Chatterji M, Radha DR, Visweswariah SS, Nagaraja V.

Nucleic Acids Res. 2002 May 15;30(10):2144-53.

30.

Monoclonal antibodies to mycobacterial DNA gyrase A inhibit DNA supercoiling activity.

Manjunatha UH, Mahadevan S, Visweswariah SS, Nagaraja V.

Eur J Biochem. 2001 Apr;268(7):2038-46.

31.

A Mycobacterium smegmatis gyrase B specific monoclonal antibody reveals association of gyrase A and B subunits in the cell.

Manjunatha UH, Somesh BP, Nagaraja V, Visweswariah SS.

FEMS Microbiol Lett. 2001 Jan 1;194(1):87-92.

Supplemental Content

Loading ...
Support Center